Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
Emil Hagström, Philippe Gabríel Steg, Michael J. Szarek, Deepak L. Bhatt et autres
BACKGROUND: Apolipoprotein B (apoB) provides an integrated measure of atherogenic risk. Whether apoB levels and apoB lowering hold incremental predictive information on residual risk after acute coronary syndrome beyond that provided by low-density lipoprotein cholesterol is uncertain. METHODS: The ODYSSEY OUTCOMES trial …
se, ru, fr, gb, us, ar, ca, nl, gr, de, nz (code pays fourni par la source)